Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Pregabalin(click to collapse)
1/4 selected
Pregabalin
Lyrica
Gabapentinoid (Calcium Channel Alpha-2-Delta Ligand) · C-V
FDA-approved indications
- Diabetic peripheral neuropathic pain (adults)
- Postherpetic neuralgia (adults)
- Partial-onset seizures — adjunct (adults; pediatric 1 month+)
- Fibromyalgia (adults)
Off-label uses
- Generalized anxiety disorder
- Social anxiety disorder
- Alcohol withdrawal
Half-life6 hours
Decision GuideWhen to pick each / when to consider an alternative
Pregabalin
Consider when
- Fibromyalgia — FDA-approved for fibromyalgia; one of only three FDA-approved agents (with duloxetine, milnacipran)
- Neuropathic pain (DPN, PHN, spinal cord injury) — FDA-approved for multiple neuropathic pain indications; broader pain coverage than gabapentin
- GAD (off-label in US, approved in EU) — EMA-approved for GAD; evidence-based anxiolytic with faster onset than SSRIs
- Linear pharmacokinetics — predictable dose-response; no saturable absorption unlike gabapentin; more reliable at higher doses
- +1 more
Consider an alternative when
- Substance use disorder — Schedule V controlled substance (only gabapentinoid scheduled federally); documented abuse/euphoria potential
- Weight gain is unacceptable — dose-dependent weight gain; worse than gabapentin; problematic in metabolic syndrome
- Dizziness or somnolence intolerable — most common AEs (29% and 16%); dose-dependent; may limit titration
- Peripheral edema — dose-dependent edema; may complicate CHF or conditions where fluid retention is problematic
- +1 more
| Axis | Pregabalin gabapentinoid |
|---|---|
| Boxed Warnings | |
Abuse / addiction liability | |
Respiratory depression (opioid / CNS depressant co-use) | |
| CNS | |
Sedation / somnolence | |
Cognitive dulling / anterograde amnesia | |
Dizziness | |
| Metabolic | |
Weight gain | |
| Sensory | |
Visual disturbances (blurred vision, diplopia, lens changes) | |
| Cardiac | |
Cardiac conduction / AV block | |
| GI | |
Nausea / GI (general) | |
| Dermatologic | |
Rash (including SJS/TEN, pruritus, hypersensitivity) | |
| Interactions | |
CYP interactions / DDI profile | |
| Safety | |
Bleeding risk | |
| Drug-specific / distinctive axes | |
Axis 4 — Peripheral edema (labeled W&P 5.7) only in Pregabalin | |
Axis 14 — Tumorigenic potential (W&P 5.9) only in Pregabalin | |